Despite the revolutionary success, loss of surface BCMA antigen on MM cells, expansion of BCMA-negative clones, T-cell dysfunction, and the immunosuppressive milieu contribute to relapses, which remain a major concern [241,242]. Here, TNFRSF17 is linked to Miyoshi myopathy.